| 前收市價 | 52.59 |
| 開市 | 51.99 |
| 買盤 | 53.94 x 無 |
| 賣出價 | 54.18 x 無 |
| 今日波幅 | 51.57 - 54.13 |
| 52 週波幅 | 51.57 - 154.76 |
| 成交量 | |
| 平均成交量 | 242 |
| 市值 | 20.807十億 |
| Beta 值 (5 年，每月) | 1.66 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -13.98 |
| 業績公佈日 | 2024年10月31日 - 2024年11月04日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 無 |
BloombergCDC Probes If Bird Flu Mutations Impact Vaccine Stockpile
(Bloomberg) -- The Centers for Disease Control and Prevention is investigating whether the US stockpile of bird flu vaccines is still well matched to the virus after discovering recent mutations. Most Read from BloombergThe Cablebus Transformed Commutes in Mexico City’s Populous OutskirtsAs Brussels Booms, an Old Boogeyman Returns: BrusselizationSan Francisco to Shut 9% of Public Schools Amid Budget WoesChicago Marathon to Honor Kenyan Who Died After His World RecordChicago’s $1 Billion Budget H
BloombergCovid-Shot Maker Goes Bankrupt After Trailing Pfizer, Moderna
(Bloomberg) -- Gritstone Bio Inc., a vaccine developer that once touted its ability to make a next-generation Covid-19 shot, filed for Chapter 11 bankruptcy in Delaware Thursday. Most Read from BloombergThe Cablebus Transformed Commutes in Mexico City’s Populous OutskirtsSan Francisco to Shut 9% of Public Schools Amid Budget WoesChicago’s $1 Billion Budget Hole Exacerbated by School TurmoilUrban Heat Stress Is Another Disparity in the World’s Most Unequal NationShould Evictions Be Banned After H
ZacksGSK Posts New Data From Phase III Study on RSV Vaccine Arexvy
New data from GSK's phase III study evaluating a single dose of RSV vaccine Arexvy indicates protection over three RSV seasons in adults aged 60 years and above.
